Assistant Professor at Wayne State University. Head & Neck Oncologic Surgeon. Health services, quality improvement & outcomes researcher. All opinions my own.
Detroit, MI
Joined June 2009
- Tweets353
- Following211
- Followers293
- Likes318
John Cramer, MD retweeted
#ESMO2026
Compelling data from investigators of KN412 on ctDNA to prognosticate
Baseline and rapid clearance of ctDNA were highly prognostic in HPV- HNSCC
More evidence supporting #PrecisionOncology in #HeadNeckCancer 💪🏻💪🏻💪🏻
John Cramer, MD retweeted
Breaking News! 🗞️ Published today in @JCO_ASCO and presented simultaneously at @myESMO. Long-term survival remains excellent 📈 after #neoadjuvant #Immunotherapy for advanced resectable @SquamousCscc #skincancer. #OncSurgery #EndCancer @UTMDAnderson
ascopubs.org/doi/10.1200/JCO…
John Cramer, MD retweeted
In a phase 1 study, RXRG001, a circular RNA encoding aquaporin-1, was administered to six patients with radiation-induced xerostomia. Measures of salivary flow improved, and adverse events were of grade 1 or 2 and transient. Full study results: nej.md/4BiCyUy
ALT A graph shows scores on the Xerostomia Questionnaire, a validated eight-item instrument for assessing the severity and effect of dry mouth on daily life as reported by the patient.
John Cramer, MD retweeted
Superstar Kevin Harrington joins us to discuss conference updates galore it’s a great summary of all the hot topics!
@DavidSherMD @drdavidpalma @HNSurgeon please RT and share! #hn #headandneck #hncsm
open.spotify.com/episode/1cA…
John Cramer, MD retweeted
NEW: Clinical Practice Guideline Update on Tinnitus gives clinicians evidence-based tools for diagnosis and treatment, built on a decade of new research.
About 50% of adults with #tinnitus talk to a clinician, but only 20% seek treatment.
Explore the CPG: hubs.ly/Q04B0_kK0
John Cramer, MD retweeted
Big melanoma data in @NatureMedicine 👇
A pooled analysis of 1,038 patients with resectable melanoma treated before surgery. Among the 735 who received immunotherapy, 58% had little or no viable tumor left at surgery.
Those patients? ~98% alive at 5 years.
And their 5-year recurrence-free survival was similar with or without additional immunotherapy after surgery (90.8% vs 90.6%).
So if treatment already worked this well, do patients need more?
Not randomized, so prospective trials are needed. But very encouraging.
John Cramer, MD retweeted
Exciting progress in bilateral vocal-fold paralysis! We show that bilateral neuromuscular laryngeal pacing can improve fbreathing, while preserving voice and swallowing. This reversible alternative t could be a game-changer for this disease #MedTwitter #LaryngealPacing #NEJM
John Cramer, MD retweeted
Topical Antiseptic or Antimicrobial Preparation for Oral Cavity Surgery: Is It Necessary and Does It Help? Read more in this Trio Best Practice: doi.org/10.1002/lary.70273
#ENTSurgery
John Cramer, MD retweeted
🌎👋@NRGonc #HN009 p16-neg #ASTRO26; Dr. Paul Harari @UWMadison
➡️Diff AE profiles b/w Q1 vs Q3
➡️6 mo LRF diff 5% (Q1 9.6% & Q3 4.6%; 95%CI 1.0-8.9) Longer FU needed.
@DanielMaMD @quyhnhi99 @imrtlee @JamesBatesMD
@JJCaudell @drlorenmell @seanmmcbride @xrtGenomics
@ASTRO_org
John Cramer, MD retweeted
The bolus versus weekly cisplatin debate rages on, but fortunately more data dropped this past week with the publication of the ConCERT trial (Concurrent Chemotherapy and External Radiation Therapy) comparing bolus with weekly schedules.
Some thoughts on this trial and the cisplatin schedules below.
academic.oup.com/jnci/articl…
John Cramer, MD retweeted
POD alert!!!! Latest effort with @DrNeilGross talking to us about his work in the NMSC space - it's a belter.
open.spotify.com/episode/3pA…
@VinPaleri @HNSurgeon @DrUppaluri @AriRosenbergMD @PBlanchardMD @drdavidpalma @DavidSherMD @oncodaily
John Cramer, MD retweeted
Another major advance vs cancer! @ASCO #ASCO26
Personalized neoantigen mRNA vaccine 5 year follow-up vs metastatic melanoma reduced recurrence and death by 49% (on top of Keytruda)
ascopubs.org/doi/10.1200/JCO…
John Cramer, MD retweeted
What does nebulized ciprofloxacin-dexamethasone actually do to an obstructed airway?
🎙️The latest OTO Journal podcast episode breaks down a novel rabbit model of airway stenosis — and the first quantitative evidence of a promising treatment.
Listen → hubs.ly/Q04hzkr80
John Cramer, MD retweeted
Sharing the results of ReACT 1.0 in @NatureComms -- the first study to use HPV ctDNA to guide CRT de-escalation in higher risk HPV+ OPC. ctDNA metrics may improve risk stratification. Grateful to our coauthors. @Naveris_inc @DanaFarberNews @jdschoenfeld1
nature.com/articles/s41467-0…
John Cramer, MD retweeted
Clear trend: more #preference #signals in medical residency application→ less overapplication.
As signals increase, apps/applicant decline—reducing cost, noise, and inefficiency.
Better alignment + less admin burden—is it for everbody?
#OtoMatch #MedEd #GME #Match2026
John Cramer, MD retweeted
Come for the critically important data on protons for oropharyngeal cancer, stay for the beautifully written paper.
TORPEdO is out, and it is fascinating and instructive.
I will warn you upfront that this is a long thread, but there is a lot here to discuss!
thelancet.com/journals/lance…
John Cramer, MD retweeted
🚨 JAMA flags admin and access delays as safety hazards in care. In #headandneckcancer, this can derail trials & immunotherapy starts, likely worsening outcomes.
Insightful viewpoint by Drs. Hassid and Kaafarani #JAMA #OncologySafety
#Oncology #PatientSafety @MDAndersonnews
💬 Viewpoint: Administrative delays and access failures introduce patient safety risks but are rarely treated as safety events in health systems.
ja.ma/4ljWHSu
John Cramer, MD retweeted
7y in the making!!!
As I always spoke about this, the field of #NasopharyngealCarcinoma leads the way in driving individualised treatment in #HeadNeckCancer
When we published our initial idea of stratifying patients by their early treatment response using #EBVDNA back then in 2018, we decided to test our idea formally with a trial, and kudos to a very talented #biostats and willing collaborators, we came up with EP-STAR
Very glad to see it finally published today in @Nature
🍸
nature.com/articles/s41586-0…
John Cramer, MD retweeted
In 2024 we showed that Modifier 22 doesn't actually pay more for complex cases owing to higher denial rates. The @AmCollSurgeons GSCRC committee has been working on this issue ever since... see our summary of what we have tried to do and what's next:
jamanetwork.com/journals/jam…
John Cramer, MD retweeted
Time from cancer diagnosis → treatment is rising: 21 days in 2004 → 28 days in 2015.
Much is ⬆️ in stage 1 & may reflect some good - ie careful shared-decision making/planning. But how to support people during the (often) anxious wait? @NicholasZaorsky
ascopubs.org/doi/full/10.120…
